Items where authors include "Mease, P"

Export as [feed] Atom [feed] RSS
Number of items: 36.

Article

Pedersen, MB, Thinggaard, P, Geenen, R et al. (14 more authors) (2023) Biopsychosocial rehabilitation for inflammatory arthritis and osteoarthritis: A systematic review and meta‐analysis of randomized trials. Arthritis Care & Research, 75 (2). pp. 423-436. ISSN 2151-464X

Coates, LC, Tillett, W, D'Agostino, MA et al. (8 more authors) (2022) Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study. The Lancet Rheumatology, 4 (4). e262-e273. ISSN 2665-9913

Jadon, DR, Chandran, V, Ogdie, A et al. (12 more authors) (2019) Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting. The Journal of Rheumatology Supplement, 95. pp. 11-19. ISSN 0380-0903

Mease, P, Coates, LC, Helliwell, PS et al. (14 more authors) (2018) Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. The Lancet, 392 (10162). pp. 2367-2377. ISSN 0140-6736

Coates, LC orcid.org/0000-0002-4756-663X, Conaghan, PG orcid.org/0000-0002-3478-5665, D’Agostino, MA et al. (9 more authors) (2018) Remission in psoriatic arthritis—where are we now? Rheumatology, 57 (8). pp. 1321-1331. ISSN 1462-0324

Højgaard, P, Klokker, L, Orbai, A-M et al. (17 more authors) (2018) A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. Seminars in Arthritis and Rheumatism, 47 (5). pp. 654-665. ISSN 0049-0172

Coates, LC orcid.org/0000-0002-4756-663X, FitzGerald, O, Merola, JF et al. (23 more authors) (2018) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. Arthritis & Rheumatology, 70 (3). pp. 345-355. ISSN 2326-5191

Smolen, JS, Schöls, M, Braun, J et al. (34 more authors) (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 77 (1). pp. 3-17. ISSN 0003-4967

Coates, LC orcid.org/0000-0002-4756-663X, Gossec, L, Smolen, JS et al. (5 more authors) (2017) New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced. Rheumatology, 56 (8). pp. 1251-1253. ISSN 1462-0324

Taylor, AM, Phillips, K, Patel, KV et al. (36 more authors) (2016) Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. Pain, 157 (9). pp. 1836-1850. ISSN 0304-3959

Weinblatt, ME, Mease, P, Mysler, E et al. (7 more authors) (2015) The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis and Rheumatology, 67 (10). pp. 2591-2600. ISSN 2326-5191

Conference or Workshop Item

Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (10 more authors) (2022) Effect of Guselkumab a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients With Active PsA: Results From a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years. In: Canadian Rheumatology Association Annual Meeting, 02-05 Feb 2022, Online.

Rahman, P, Ritchlin, C, Mease, P et al. (10 more authors) (2022) Long-term Safety of Guselkumab in Patients With Active Psoriatic Arthritis: Pooled Results From 3 Randomized Clinical Trials Through Up to 2 Years. In: Open Access Canadian Rheumatology Association Annual Meeting, 02-05 Feb 2022, Online.

Kavanaugh, A, Liu, Y, Deodhar, A et al. (8 more authors) (2021) Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 DISCOVER Program. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Mease, P, Helliwell, PS orcid.org/0000-0002-4155-9105, Gladman, D et al. (10 more authors) (2021) Effect of Guselkumab (TREMFYA (R)), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Mease, P, Helliwell, PS orcid.org/0000-0002-4155-9105, Silwinska-Stanczyk, P et al. (11 more authors) (2021) Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Behrens, F, Mease, P, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (8 more authors) (2021) Efficacy of Guselkumab Across BASDAI Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-controlled Studies. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Mease, P, Orbai, A-M, FitzGerald, O et al. (5 more authors) (2021) Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Coates, L, Ritchlin, C, Gossec, L et al. (12 more authors) (2021) Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Rahman, P, Ritchlin, C, Mease, P et al. (11 more authors) (2021) Long-term Safety of Guselkumab (TREMFYA (R)) in Patients with Active Psoriatic Arthritis: Pooled Results from 3 Randomized Clinical Trials Through up to 2 Years. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Mease, P, Foley, P, Reich, K et al. (14 more authors) (2021) Low Incidence of Gastrointestinal-related and Overall Serious Adverse Events Among Guselkumab-treated Patients: Pooled Analyses of VOYAGE 1 & 2 and DISCOVER 1 & 2 Through 1-Year. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (12 more authors) (2021) Efficacy of Guselkumab on Axial-Related Endpoints in Patients with Active Psoriatic Arthritis with Imaging-Confirmed Sacroiliitis. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Rahman, P, Ritchlin, C, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (12 more authors) (2021) Integrated Safety Results of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis through the Placebo-Controlled Periods. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Merola, JF, Gottlieb, AB, Mease, P et al. (5 more authors) (2020) Psoriasis outcomes in a randomized trial of etanercept and methotrexate as monotherapy or in combination in patients with psoriatic arthritis. In: 2020 AAD VMX, 12-14 Jun 2020, Virtual.

Mease, P, Coates, L, Van den Bosch, F et al. (7 more authors) (2020) Effect of Filgotinib on the Complete Resolution of Enthesitis in Psoriatic Arthritis (PsA) Patients: 52-week Results from EQUATOR2. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (15 more authors) (2020) Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-52 Results from Two Phase 3, Randomized, Double-blind, Placebo-controlled Studies. In: 37º Congresso Brasileiro de Reumatologia, 19-22 Nov 2020, Virtual.

Orbai, A-M, Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (5 more authors) (2020) Efficacy of Tofacitinib on Dactylitis in Individual Digits in Patients with Active Psoriatic Arthritis. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Coates, L, Ritchlin, C, Gossec, L et al. (12 more authors) (2020) Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: ACR Convergence 2020, 05-09 Nov 2021, Virtual.

Coates, L, Gladman, D, Van den Bosch, F et al. (10 more authors) (2020) Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA). In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Helliwell, P orcid.org/0000-0002-4155-9105, Mease, P, Kavanaugh, A et al. (9 more authors) (2020) What Influence Do Clinical Domains Other Than Arthritis Have on Composite Clinical Outcomes in Psoriatic Arthritis?: Comparison of Treatment Effects in the SEAM-PsA Trial. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Coates, L, Mease, P, Gladman, D et al. (8 more authors) (2020) Long-Term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study. In: British Society for Rheumatology Annual Conference 2020, 20-22 Apr 2020.

Coates, L, Mease, P, Gladman, D et al. (8 more authors) (2020) Long-term safety of filgotinib in patients with PsA: week 52 safety data from a Phase 2 open-label extension study. In: British Society for Rheumatology Annual Conference 2020, 20-22 Apr 2020, Cancelled.

Coates, L, Mease, P, Gladman, D et al. (8 more authors) (2019) Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study. In: 2019 ACR/ARP Annual Meeting Minutes, 08-13 Nov 2019, Atlanta, Georgia, USA.

Coates, L, Merola, J, Mease, P et al. (10 more authors) (2019) The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, Georgia, USA.

Helliwell, P, Gottlieb, AB, Deodhar, A et al. (7 more authors) (2019) The Effect of Guselkumab on Enthesitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis. In: Pan-American Congress of Rheumatology 2019, 27-30 Apr 2019, Quito, Ecuador.

Proceedings Paper

McInnes, I, Mease, P, Hjuler, KF et al. (2 more authors) (2019) Brodalumab in psoriatic arthritis (PsA): 24-week results from the phase III AMVISON-1 and -2 trials. In: Journal of the American Academy of Dermatology. AAD 2019: American Academy of Dermatology Annual Meeting, 01-05 Mar 2019, Washington, DC, USA. Elsevier , AB28-AB28.

This list was generated on Sun Mar 24 08:06:45 2024 GMT.